These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 35477319)

  • 1. Emerging therapies for ulcerative colitis.
    Hanzel J; Hulshoff MS; Grootjans J; D'Haens G
    Expert Rev Clin Immunol; 2022 May; 18(5):513-524. PubMed ID: 35477319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive overview of novel chemical drugs for ulcerative colitis: focusing on phase 3 and beyond.
    Neri B; Mancone R; Fiorillo M; Schiavone SC; De Cristofaro E; Migliozzi S; Biancone L
    Expert Opin Pharmacother; 2024 Apr; 25(5):485-499. PubMed ID: 38591242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials.
    Neurath L; D'Amico F; Danese S
    Expert Opin Emerg Drugs; 2023 Mar; 28(1):27-42. PubMed ID: 36876333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors.
    Goetsch A; D'Amico F; Allocca M; Fiorino G; Furfaro F; Zilli A; Parigi TL; Radice S; Peyrin-Biroulet L; Danese S
    Expert Opin Pharmacother; 2023 May; 24(7):849-861. PubMed ID: 37038911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.
    Misselwitz B; Juillerat P; Sulz MC; Siegmund B; Brand S;
    Digestion; 2020; 101 Suppl 1():69-82. PubMed ID: 32570252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: emerging drug therapies in inflammatory bowel disease.
    Grossberg LB; Papamichael K; Cheifetz AS
    Aliment Pharmacol Ther; 2022 Apr; 55(7):789-804. PubMed ID: 35166398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment.
    Nakase H
    Immunol Med; 2023 Sep; 46(3):121-130. PubMed ID: 37036140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-interleukin-23 agents for the treatment of ulcerative colitis.
    Hanžel J; D'Haens GR
    Expert Opin Biol Ther; 2020 Apr; 20(4):399-406. PubMed ID: 31760827
    [No Abstract]   [Full Text] [Related]  

  • 9. Filgotinib for moderately to severely active ulcerative colitis.
    Mannucci A; D'Amico F; El Saadi A; Peyrin-Biroulet L; Danese S
    Expert Rev Gastroenterol Hepatol; 2022 Oct; 16(10):927-940. PubMed ID: 36278878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mirikizumab for the treatment of moderate to severe ulcerative colitis.
    Hanzel J; Ma C; Jairath V
    Immunotherapy; 2023 Oct; 15(15):1199-1208. PubMed ID: 37465925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning.
    Fudman D; McConnell RA; Ha C; Singh S
    Clin Gastroenterol Hepatol; 2024 Aug; ():. PubMed ID: 39147217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovations in Oral Therapies for Inflammatory Bowel Disease.
    Ma C; Battat R; Dulai PS; Parker CE; Sandborn WJ; Feagan BG; Jairath V
    Drugs; 2019 Aug; 79(12):1321-1335. PubMed ID: 31317509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials.
    D'Amico F; Fiorino G; Furfaro F; Allocca M; Danese S
    Expert Opin Investig Drugs; 2018 Jul; 27(7):595-599. PubMed ID: 29938545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of sphingosine-1-phosphate in ulcerative colitis.
    Argollo M; Furfaro F; Gilardi D; Roda G; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2020 Apr; 20(4):413-420. PubMed ID: 32093531
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
    Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.
    Núñez P; Quera R; Yarur AJ
    Drugs; 2023 Mar; 83(4):299-314. PubMed ID: 36913180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis.
    Rowan C; Ungaro R; Mehandru S; Colombel JF
    Expert Opin Pharmacother; 2022 Jun; 23(8):893-904. PubMed ID: 35503955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Upadacitinib As a Second-line JAK Inhibitor in Ulcerative Colitis: A Case Series.
    Hosomi S; Nishida Y; Fujiwara Y
    Intern Med; 2024 Jul; 63(13):1882-1885. PubMed ID: 38008454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule drugs in the treatment of inflammatory bowel diseases: which one, when and why? - a systematic review.
    Lucaciu LA; Seicean R; Seicean A
    Eur J Gastroenterol Hepatol; 2020 Jun; 32(6):669-677. PubMed ID: 32282548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Therapeutics for Ulcerative Colitis.
    Hirten RP; Sands BE
    Annu Rev Med; 2021 Jan; 72():199-213. PubMed ID: 33502898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.